InCarda Therapeutics

Coming – April 1

A-fib Affects Millions: A New Way to Stop It in Minutes

Date and Time

April 1

–

12:00 PM ET / 9:00 AM PT

Details will be provided upon RSVP approval

About this Event

Atrial fibrillation, or “A-fib,” is far more common than most people realize. More than 10 million Americans live with it today, and chances are you know a parent, spouse, or close friend who has experienced the sudden, racing, irregular heartbeat, hospital visits, and ongoing stroke risk that come with this condition.

InCarda Therapeutics has created a new approach to treating A-fib at the moment patients need help most: when an episode begins. The company is developing rapid, safe pharmacologic cardioversion therapies designed to restore normal heart rhythm both in the hospital and, ultimately, at home; potentially avoiding emergency admissions, anesthesia, and prolonged hospital stays.

Led by experienced cardiovascular pharmaceutical industry executives and physicians, InCarda combines two well-understood anti-arrhythmic medicines into a treatment that is greater than the sum of its parts; a fast-acting therapy that converts A-fib quickly and safely, addressing a major gap in today’s standard of care. The opportunity spans an estimated $2B in-hospital market and a $6B at-home market in the U.S. alone.

Join our online event with Dr. Myles Greenberg, InCarda President & CEO, to hear how with extensive clinical experience, strong intellectual property, and a capital-efficient development pathway, InCarda is advancing toward key clinical milestones that could reshape how A-fib is managed worldwide.

Sign Up Today

SHARE THIS EVENT

This presentation contains forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical facts and referenced statistics, contained in this presentation, including statements regarding future company strategy, operations, financial position, revenues, projected costs, plans and objectives of management, will be forward-looking statements.

All statements and expressions are the sole opinion of the company and are subject to change without notice. The Company is not liable for any investment decisions by its readers or subscribers. It is strongly recommended that any purchase or sale decision be discussed with a financial advisor, or a broker-dealer, or a member of any financial regulatory bodies. The information contained herein has been provided as an information service only. The accuracy or completeness of the information is not warranted and is only as reliable as the sources from which it was obtained. Investors are cautioned that they may lose all or a portion of their investment in this or any other company. Information contained herein contains “forward looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities and Exchange Act of 1934, as amended. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions or future events or performance are not statements of historical facts and may be “forward looking statements”. Forward looking statements are based on expectations, estimates and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of words such as “expects”, “will”, “anticipates”, “estimates”, “believes”, or by statements indicating certain actions “may”, “could”, “should” or “might” occur.